Literature DB >> 20428110

Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.

Celia J A Morgan1, Tom P Freeman, Gráinne L Schafer, H Valerie Curran.   

Abstract

Worldwide cannabis dependence is increasing, as is the concentration of Delta(9)-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabinoids have opposing effects both pharmacologically and behaviorally when administered in the laboratory. No research has yet examined how the ratio of these constituents impacts on the appetitive/reinforcing effects of cannabis in humans. A total of 94 cannabis users were tested 7 days apart, once while non-intoxicated and once while acutely under the influence of their own chosen smoked cannabis on dependence-related measures. Using an unprecedented methodology, a sample of cannabis (as well as saliva) was collected from each user and analyzed for levels of cannabinoids. On the basis of CBD : THC ratios in the cannabis, individuals from the top and bottom tertiles were directly compared on indices of the reinforcing effects of drugs, explicit liking, and implicit attentional bias to drug stimuli. When intoxicated, smokers of high CBD : THC strains showed reduced attentional bias to drug and food stimuli compared with smokers of low CBD : THC. Those smoking higher CBD : THC strains also showed lower self-rated liking of cannabis stimuli on both test days. Our findings suggest that CBD has potential as a treatment for cannabis dependence. The acute modulation of the incentive salience of drug cues by CBD may possibly generalize to a treatment for other addictive disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428110      PMCID: PMC2906701          DOI: 10.1038/npp.2010.58

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  33 in total

1.  Selective processing of cannabis cues in regular cannabis users.

Authors:  Matt Field; Brian Eastwood; Brendan P Bradley; Karin Mogg
Journal:  Drug Alcohol Depend       Date:  2006-05-15       Impact factor: 4.492

2.  Attentional bias predicts heroin relapse following treatment.

Authors:  Marlies A E Marissen; Ingmar H A Franken; Andrew J Waters; Peter Blanken; Wim van den Brink; Vincent M Hendriks
Journal:  Addiction       Date:  2006-09       Impact factor: 6.526

3.  The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users.

Authors:  M Gossop; S Darke; P Griffiths; J Hando; B Powis; W Hall; J Strang
Journal:  Addiction       Date:  1995-05       Impact factor: 6.526

4.  Are choice and self-administration of marijuana related to delta 9-THC content?

Authors:  T H Kelly; R W Foltin; C S Emurian; M W Fischman
Journal:  Exp Clin Psychopharmacol       Date:  1997-02       Impact factor: 3.157

5.  Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward.

Authors:  Stephen V Mahler; Kyle S Smith; Kent C Berridge
Journal:  Neuropsychopharmacology       Date:  2007-04-04       Impact factor: 7.853

6.  Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users.

Authors:  Derik Hermann; Alexander Sartorius; Helga Welzel; Sigrid Walter; Gisela Skopp; Gabriele Ende; Karl Mann
Journal:  Biol Psychiatry       Date:  2007-01-17       Impact factor: 13.382

Review 7.  Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Authors:  A W Zuardi; J A S Crippa; J E C Hallak; F A Moreira; F S Guimarães
Journal:  Braz J Med Biol Res       Date:  2006-04-03       Impact factor: 2.590

Review 8.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.

Authors:  Linda A Parker; Page Burton; Robert E Sorge; Christine Yakiwchuk; Raphael Mechoulam
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

Review 10.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

Authors:  Robin Christensen; Pernelle Kruse Kristensen; Else Marie Bartels; Henning Bliddal; Arne Astrup
Journal:  Lancet       Date:  2007-11-17       Impact factor: 79.321

View more
  66 in total

Review 1.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 2.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

Review 3.  Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

Authors:  John M McPartland; Marnie Duncan; Vincenzo Di Marzo; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-02       Impact factor: 8.739

4.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors:  Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  Drug Alcohol Depend       Date:  2016-02-23       Impact factor: 4.492

5.  Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Authors:  Charlotte Klein; Emily Karanges; Adena Spiro; Alexander Wong; Jarrah Spencer; Thanh Huynh; Nathan Gunasekaran; Tim Karl; Leonora E Long; Xu-Feng Huang; Kelly Liu; Jonathon C Arnold; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2011-06-11       Impact factor: 4.530

Review 6.  Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Authors:  Ethan B Russo
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 7.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

Review 8.  Spicing things up: synthetic cannabinoids.

Authors:  Max Spaderna; Peter H Addy; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

9.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

Authors:  Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran
Journal:  Lancet Psychiatry       Date:  2020-07-28       Impact factor: 27.083

10.  Dopamine, urges to smoke, and the relative salience of drug versus non-drug reward.

Authors:  Tom P Freeman; Ravi K Das; Sunjeev K Kamboj; H Valerie Curran
Journal:  Soc Cogn Affect Neurosci       Date:  2014-02-12       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.